We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Intra-Cellular Therapies (ITCI - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Intra-Cellular Therapies is a member of our Medical group, which includes 1182 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Intra-Cellular Therapies is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ITCI's full-year earnings has moved 14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ITCI has gained about 0.1% so far this year. Meanwhile, the Medical sector has returned an average of -16.3% on a year-to-date basis. As we can see, Intra-Cellular Therapies is performing better than its sector in the calendar year.
RxSight, Inc. (RXST - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 5%.
The consensus estimate for RxSight, Inc.'s current year EPS has increased 5.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Intra-Cellular Therapies belongs to the Medical - Biomedical and Genetics industry, which includes 557 individual stocks and currently sits at #63 in the Zacks Industry Rank. On average, this group has lost an average of 17.6% so far this year, meaning that ITCI is performing better in terms of year-to-date returns.
RxSight, Inc. however, belongs to the Medical - Instruments industry. Currently, this 103-stock industry is ranked #87. The industry has moved -27.7% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Intra-Cellular Therapies and RxSight, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Intra-Cellular Therapies (ITCI - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Intra-Cellular Therapies is a member of our Medical group, which includes 1182 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Intra-Cellular Therapies is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ITCI's full-year earnings has moved 14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ITCI has gained about 0.1% so far this year. Meanwhile, the Medical sector has returned an average of -16.3% on a year-to-date basis. As we can see, Intra-Cellular Therapies is performing better than its sector in the calendar year.
RxSight, Inc. (RXST - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 5%.
The consensus estimate for RxSight, Inc.'s current year EPS has increased 5.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Intra-Cellular Therapies belongs to the Medical - Biomedical and Genetics industry, which includes 557 individual stocks and currently sits at #63 in the Zacks Industry Rank. On average, this group has lost an average of 17.6% so far this year, meaning that ITCI is performing better in terms of year-to-date returns.
RxSight, Inc. however, belongs to the Medical - Instruments industry. Currently, this 103-stock industry is ranked #87. The industry has moved -27.7% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Intra-Cellular Therapies and RxSight, Inc. as they could maintain their solid performance.